Tech Company Financing Transactions
CoMentis Funding Round
On 9/28/2006, CoMentis secured $50 million in Series B funding from Clarus, Sanderling Ventures and CLS.
Transaction Overview
Company Name
Announced On
9/28/2006
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
Proceeds Purpose
The funds will be used primarily to advance development of the company's lead programs targeting Alzheimer's disease, age-related macular degeneration (AMD) and cognition enhancement.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Oyster Point Blvd. 226
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Not Recorded
Overview
CoMentis is a biotech company engaged in the research and development of small molecule drugs to treat neurovascular diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Terence Kelly
VP - General Counsel
Daniel Hunt
VP - R & D
John Ng
Browse more venture capital transactions:
Prev: 9/28/2006: Demand Media venture capital transaction
Next: 9/29/2006: NovaCardia venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs